Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

NP-101 before Y-90 Radioembolization for the Treatment of Unresectable Hepatocellular Carcinoma

Trial Status: active

This phase I trial studies the side effects and best dose of NP-101 when given before yttrium-90 (Y-90) radioembolization in patients with hepatocellular carcinoma (HCC) that cannot be removed by surgery (unresectable). NP-101 is an oral supplement made from black seeds (also known as black cumin or Nigella sativa) that grows in Southern Europe, North Africa, the Middle Eastern Mediterranean region, and Southwest Asia. NP-101 has special qualities that could help with certain types of cancer. It may help stop the growth of tumor cells and make them die off. Y-90 radioembolization is a therapy that injects radioactive particles directly into an artery that feeds liver tumors to cut off their blood supply. Giving NP-101 before Y-90 radioembolization may be safe, tolerable, and/or effective in treating patients with unresectable HCC.